Treatment Differences and 95% CI for Secondary Outcomes, Adjusted for Age, Gender, Baseline Value of the Dependent Variable, Headache Type, and Geographical Locality at 4-, 8- and 12-Month Follow-ups
USD28,600, Anxiety
INTERACTIONS
Abbreviations: nC, number of participants from standard care; nSM, number of participants from self-management. Estimates and 95% CI rescaled to range from 0 to 100 for graphical representation purposes only. To obtain the estimated difference and its 95% CI in its original scale, the value from graph is multiplied by maximum value/100. For example, the estimated difference for HADS Anxiety at 4-month FU was −0.801 × 21/100 = −0.16821). See also eTables 17–19 (Treatment Effects and Treatment by Subgroup Interactions for Subgroup Analyses of the 12-Mo HIT-6 OutcomeThere were 7 AEs, 1 in the standard care arm and 6 in the self-management arm. There was 1 SAE; a participant in the standard care arm died of an unrelated cause (eTable 26, The CHESS intervention generated incremental adjusted costs of £268 (95% CI £176–£377) [USD383 (95%CI USD252–USD539)] and incremental adjusted QALYs of 0.031 (95% CI −0.005 to 0.063). The incremental cost-effectiveness ratio was £8,617 (USD12,322) per QALY gained. The incremental net monetary benefit was £354 (95% CI −£375 to £1,084) [USD506 (95% CI −USD536 to USD1,550)] with probability that the intervention is cost-effective, approaching 0.83 if the cost-effectiveness threshold is £20,000 (USD28,600) per QALY gained (